Analysts Mixed On Premium For Pharmacyclics By: Benzinga via Benzinga March 05, 2015 at 16:48 PM EST AbbVie Inc (NYSE: ABBV) $21 billion deal to acquire Pharmacyclics, Inc. (NASDAQ: PCYC) Thursday drew mixed reviews from analysts and ... Read More >> Related Stocks: AbbVie